Marshall Wace, LLP Altimmune, Inc. Transaction History

Marshall Wace, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.14 - $11.62 $3.66 Million - $19.9 Million	-1,712,608 Reduced 95.21%	86,132 $968,000
Q3 2023 Nov 14, 2023	SELL	$2.4 - $3.45 $625,320 - $898,897	-260,550 Reduced 12.65%	1,798,740 $4.68 Million
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $1.59 Million - $2.76 Million	462,160 Added 28.94%	2,059,290 $7.27 Million
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $1.5 Million - $6.01 Million	357,336 Added 28.82%	1,597,130 $6.74 Million
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $1.23 Million - $2.32 Million	140,880 Added 12.82%	1,239,794 $20.4 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $8.84 Million - $18.6 Million	828,584 Added 306.51%	1,098,914 $14 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $1.07 Million - $3.18 Million	270,330 New	270,330 $3.16 Million
Q4 2021 Feb 14, 2022	SELL	$8.69 - $12.48 $4.16 Million - $5.98 Million	-478,923 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $3.79 Million - $7.56 Million	-449,793 Reduced 48.43%	478,923 $5.42 Million
Q2 2021 Aug 13, 2021	BUY	$9.85 - $16.46 $9.15 Million - $15.3 Million	928,716 New	928,716 $9.15 Million
Q1 2021 May 17, 2021	SELL	$12.71 - $24.31 $394,632 - $754,801	-31,049 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $243,424 - $441,516	31,049 New	31,049 $350,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.